Adicet Bio, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period
Adicet Bio, Inc. (ACET) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period of 50.14 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod · last filed 2026-08-05
- Adicet Bio, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2026-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- Adicet Bio, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2026-03-31 was 50.14K shares, a 90.92% decline year-over-year.
- Adicet Bio, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2025-12-31 was -580.65K shares.
- Adicet Bio, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2025-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- Adicet Bio, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2025 was 38.65K shares, a 92.81% decline from fiscal 2024.
- Adicet Bio, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2024 was 537.40K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | 50.14K shares 10-Q · filed 2026-08-05 | -530.51K shares derived: sum of 3 quarters · filed 2026-08-05 | -530.51K shares derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | 50.14K shares 10-Q · filed 2026-05-13 | -530.51K shares derived: sum of 2 quarters · filed 2026-05-13 | -530.51K shares derived: sum of 3 quarters · filed 2026-05-13 | -463.61K shares derived: sum of 4 quarters · filed 2026-05-13 |
| 2025-12-31 | -580.65K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -580.65K shares derived: sum of 2 quarters · filed 2026-03-12 | -513.75K shares derived: sum of 3 quarters · filed 2026-03-12 | 38.65K shares 10-K · filed 2026-03-12 |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | 66.90K shares derived: sum of 2 quarters · filed 2025-11-05 | 619.30K shares 10-Q · filed 2025-11-05 | 619.30K shares derived: sum of 4 quarters · filed 2025-11-05 |
| 2025-06-30 | 66.90K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 619.30K shares 10-Q · filed 2025-08-07 | 619.30K shares derived: sum of 3 quarters · filed 2025-08-07 | 627.10K shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | 552.40K shares 10-Q · filed 2025-05-06 | 552.40K shares derived: sum of 2 quarters · filed 2025-05-06 | 560.20K shares derived: sum of 3 quarters · filed 2025-05-06 | 601.50K shares derived: sum of 4 quarters · filed 2025-05-06 |
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | 7.80K shares derived: sum of 2 quarters · filed 2025-03-06 | 49.10K shares derived: sum of 3 quarters · filed 2025-03-06 | 537.40K shares 10-K · filed 2025-03-06 |
| 2024-09-30 | 7.80K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | 49.10K shares derived: sum of 2 quarters · filed 2024-11-06 | 537.40K shares 10-Q · filed 2024-11-06 | |
| 2024-06-30 | 41.30K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | 529.60K shares 10-Q · filed 2024-08-13 | ||
| 2024-03-31 | 488.30K shares 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |